'Restenosis' presentation slideshows

Drug Eluting Versus Bare Metal Stents

Drug Eluting Versus Bare Metal Stents. Prof. Dr. Raouf Mahran ;MRCP Prof. of cardiovasc. Med National Heart Institute 2009. Historical back grounds. Evolution of PCI. 1977: Balloon Angioplasty (POBA) 1994: Bare Metal Stent (BMS) 2003: Drug Eluting Stent (DES).

1.65k views • 87 slides

Clinical Writing for Interventional Cardiologists

Clinical Writing for Interventional Cardiologists. What you will learn - hopefully!. Introduction General principles for clinical writing Specific techniques Practical session: critical review of a published article Writing the Title and the Abstract

417 views • 26 slides

Pathologic Intimal Hyperplasia as a Response to Vascular Injury and Reconstruction

Pathologic Intimal Hyperplasia as a Response to Vascular Injury and Reconstruction. Background. Ebolectomy catheter induced intimal thickening (accumulation of smooth muscle cells [SMCs] and extracellular matrix)

267 views • 26 slides

Cath Conference

575 views • 24 slides

Radiation for restenosis: the dark side of arteries

Radiation for restenosis: the dark side of arteries. hot. Robert S Schwartz MD Professor of Medicine Mayo Clinic Rochester, MN. Figure 1. Stimulation of neointima within an irradiated artery. Figure 2. Minimal neointimal neoplasia post stent placement. External beam radiation.

340 views • 24 slides

WE NEED A DEDICATED STENT

WE NEED A DEDICATED STENT. PHILIPPE GUYON. An Evidence Based Medicine:. Surgery is the unique validated option to treat a left main coronary disease. Left Main PTCA Validation. Battling: Restenosis Stent Thrombosis Widely reproductive. Do we meet this goal?.

233 views • 23 slides

9 th month study

9 th month study. P. Buszman 1,2 , R. Gil 3 , J. Rzezniczak 4 , T. Przewlocki 5 , M. Kosmider 6 , J. Wojcik 7 , J. Janczak 8 , S. Trznadel 2 , L. Kinasz 2 , M. Kondys 2 , M. Krol 2 , K. Milewski 1,2. 1. Silesian Medical School , Katowice 2. American Heart of Poland , Ustron

402 views • 19 slides

SIRIUS Trial: Diameter Restenosis

SIRIUS Trial: Diameter Restenosis. P<0.001. P=0.001. % Proximal Segment. % In Segment. % Distal Segment. % In stent. P=NS. P=0.14. Coated. Bare. Coated. Bare. Coated. Bare. Coated. Bare. Peristent Restenosis (PSR): 5 mm proximal and distal to the stent

256 views • 9 slides

Presented at The American College of Cardiology Scientific Session 2006

Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial. Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Rainer Wessley. RES and PES with Identical Biodegradable Polymeric Coating and Design: Background.

170 views • 7 slides

Restenosis at six months in HD patients with elevated vs normal PTH levels

Restenosis at six months in HD patients with elevated vs normal PTH levels. Kubo T et al. European Society of Cardiology Congress 2005 ; September 4-7, 2005; Stockholm, Sweden. Multivariate predictors of angiographic restenosis at six months.

113 views • 3 slides